From the Histological Model to the Mutational Model: The Study of Heavy Metals and Other Substances in New Antineoplastic Therapies

Abstract

The study of genetic mutations in tumours changes the therapeutic approach; in fact, we move into a different advanced and strategic phase by entering personalized precision medicine and shifting the focus from the tissue study of the tumour to the modification and proliferation of neoplastic cells. The therapeutic programs, especially in oncology, are changing. We are in a phase of transition from the histological model to the model of genetic mutation (mutation). When a person's immune defences do not respond to a disease it is because the body cannot produce or activate specific lymphocytes and antibodies against that disease. This causes of a lack of therapeutic response or recurrence of the disease. A fundamental role is played by genomic tests, which are carried out directly on the neoplastic tissue and other modifies tissues, and the dosage of toxic substances (heavy metals, dioxins, furans, PCBs, etc.) analysed 'primarily' in the tumour and subsequently in the various biological matrices (tissues, modified, blood, urine, hair, nails, breast milk, saliva, etc.) as well as genetic tests. A significant role is a search for toxic substances and therapeutic integration of trace elements beneficial for cellular metabolism, especially for defence mechanisms, absent or deficient in these patients, such as Copper, Selenium, Zinc, Cobalt, Iron, and Manganese to improve or modify a lack of therapeutic response. Another parameter to consider is hyperglycaemia in diabetic subjects, which according to various scientific research, is considered a personal risk factor not so much in the formation phase of the neoplastic disease, but in the healing response phase.